S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
pixel
Log in
NASDAQ:ADMS

Adamas Pharmaceuticals Earnings Date, Estimates & History

$5.26
+0.23 (+4.57 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.07
Now: $5.26
$5.54
50-Day Range
$4.46
MA: $5.37
$6.79
52-Week Range
$1.90
Now: $5.26
$9.15
Volume668,802 shs
Average Volume916,610 shs
Market Capitalization$160.79 million
P/E RatioN/A
Dividend YieldN/A
Beta2.96

Earnings

Adamas Pharmaceuticals (NASDAQ:ADMS) Earnings Information

Adamas Pharmaceuticals last announced its quarterly earnings data on February 22nd, 2021. The specialty pharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.11. Adamas Pharmaceuticals has generated ($3.80) earnings per share over the last year. Adamas Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 6th, 2021 based off prior year's report dates.

Adamas Pharmaceuticals Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Adamas Pharmaceuticals (NASDAQ:ADMS) Earnings Estimates

2021 EPS Consensus Estimate: ($1.67)
2022 EPS Consensus Estimate: ($0.89)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20214($0.57)($0.45)($0.53)
Q2 20214($0.54)($0.40)($0.45)
Q3 20214($0.52)($0.31)($0.40)
Q4 20213($0.35)($0.23)($0.30)
Q1 20222($0.40)($0.28)($0.34)
Q2 20222($0.25)($0.23)($0.24)
Q3 20222($0.19)($0.18)($0.19)
Q4 20222($0.13)($0.11)($0.12)

Adamas Pharmaceuticals (NASDAQ ADMS) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSGAAP EPSRevenue EstimateActual RevenueConference CallDetails
5/6/2021
(Estimated)
       
2/22/202112/31/2020($0.53)($0.64)($0.64)Transcript
11/10/20209/30/2020($0.48)($0.42)($0.42)$21.37 million$20.18 millionListen
8/6/20206/30/2020($0.61)($0.37)($0.37)$15.63 million$18.79 millionTranscript
5/7/20203/31/2020($0.77)($0.59)($0.59)$15.07 million$14.48 millionTranscript
2/25/2020Q4 2019($0.89)($0.8271)($0.83)$16.31 million$16.35 millionTranscript
11/7/20199/30/2019($0.90)($0.99)($0.99)$14.36 million$13.93 millionTranscript
8/8/2019Q2 2019($0.98)($0.90)($0.90)$12.62 million$12.69 millionN/A
5/9/20193/31/2019($1.13)($1.08)($1.08)$12.78 million$11.67 millionN/A
3/4/2019Q4($1.36)($1.06)($1.06)$13.30 million$13.32 millionTranscript
11/1/20189/30/2018($1.34)($1.22)($1.22)$10.10 million$10.61 millionTranscript
8/2/2018Q2 2018($1.41)($1.2570)($1.26)$4.84 million$7.57 millionN/A
5/3/2018Q1 2018($1.37)($1.35)($1.35)$1.71 million$2.55 millionN/A
2/22/2018Q4 2017($1.18)($1.27)($1.27)$0.84 million$0.57 millionN/A
11/2/2017Q3 2017($1.01)($1.04)($1.04)$0.03 millionN/A
8/8/2017Q2 2017($0.81)($0.93)($0.93)$0.03 million$0.02 millionListen
5/9/2017Q1 2017($0.72)($0.72)($0.72)$0.11 millionListen
2/28/2017Q4($0.80)($0.68)($0.68)$0.17 million$0.04 millionN/A
11/3/2016Q3 2016($0.83)($0.66)($0.66)$0.26 million$0.14 millionN/A
8/4/2016Q2 2016($0.71)($0.78)($0.78)$0.18 million$0.22 millionN/A
5/10/2016Q1($0.76)($0.65)($0.65)$0.18 millionN/A
2/23/2016Q4($0.81)($0.58)($0.58)$0.10 million$0.52 millionN/A
11/12/2015Q3($0.79)($0.81)($0.81)$0.10 million$0.77 millionN/A
8/11/2015Q215($0.67)($0.78)($0.78)$0.10 million$0.40 millionN/A
5/13/2015Q414($0.74)($0.69)($0.69)$0.10 million$0.23 millionN/A
3/3/2015Q4 2014$0.64$0.50$0.50$30.18 million$30.30 millionN/A
11/4/2014Q314($0.44)($0.57)($0.57)$0.18 million$0.22 millionN/A
8/7/2014Q214$2.07$0.88$0.88$18.75 million$25.15 millionN/A
5/13/2014Q114($0.09)($0.67)($0.67)$30.60 million$0.18 millionTranscript
(Earnings results data provided by Zacks Investment Research)
This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.